P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3

Bibliographic Details
Main Authors:	A. M. Lesokhin, B. Arnulf, R. Niesvizky, M. Mohty, N. J. Bahlis, M. H. Tomasson, P. Rodrίguez-Otero, H. Quach, N. S. Raje, S. Iida, M.-S. Raab, A. Czibere, S. Sullivan, E. Leip, A. Viqueira, X. Leleu
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000846664.78859.dd

Similar Items

S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3
by: Mohamad Mohty, et al.
Published: (2023-08-01)

EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
by: N Raje, et al.
Published: (2023-10-01)

P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES
by: Salomon Manier, et al.
Published: (2023-08-01)

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY
by: M Mohty, et al.
Published: (2023-10-01)

P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3
by: Xavier Leleu, et al.
Published: (2023-08-01)

EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN–DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES
by: A Nooka, et al.
Published: (2023-10-01)

P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
by: Cyrille Touzeau, et al.
Published: (2023-08-01)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
by: Xavier Leleu, et al.
Published: (2023-08-01)

P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A
by: Paula Rodríguez-Otero, et al.
Published: (2023-08-01)

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
by: A. Dalovisio, et al.
Published: (2022-06-01)

PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
by: Sebastian Grosicki, et al.
Published: (2023-08-01)

PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: R. Fonseca, et al.
Published: (2022-06-01)

PB2131: MAGNETISMM-7: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF ELRANATAMAB VERSUS LENALIDOMIDE IN POST-TRANSPLANT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
by: Maria Victoria Mateos Manteca, et al.
Published: (2023-08-01)

P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A
by: Katja Weisel, et al.
Published: (2023-08-01)

P957: AN INDIRECT COMPARISON OF ELRANATAMAB’S (ELRA) OBJECTIVE RESPONSE RATE (ORR) FROM MAGNETISMM-3 (MM-3) VERSUS REAL-WORLD EXTERNAL CONTROL ARMS IN TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM)
by: Luciano Costa, et al.
Published: (2023-08-01)

Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma
by: Taruba Rais, et al.
Published: (2023-10-01)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
by: Benedetta Dalla Palma, et al.
Published: (2020-09-01)

Síntese e caracterização do copolímero poli(3-hidroxibutirato-co-ε-caprolactona) a partir de poli (3-hidroxibutirato) e poli(ε-caprolactona) Synthesis and characterization of the copolymer poly(3-poly(3-hydroxybutyrate)-co-ε-caprolactone) from poly(3-hydroxybutyrate) and poly(ε-caprolactone)
by: Juan P. B. Roa, et al.
Published: (2010-09-01)

Estudos sobre a toxicologia da ε-caprolactama
by: Marcus Vinicius Justo Bomfim, et al.
Published: (2009-03-01)

On <it>ε</it>-optimality conditions for multiobjective fractional optimization problems
by: Kim Gwi, et al.
Published: (2011-01-01)

US patent no. 7,643,949 B2: Coriolis mode processing
by: Henry, M
Published: (2010)

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
by: Fumou Sun, et al.
Published: (2024-01-01)

Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
by: Lijun Wu, et al.
Published: (2022-05-01)

Avaliação da biodegradação de compósitos de poli(ε-caprolactona)/fibra de coco verde Evaluation of biodegradation poly(ε-caprolactone)/green coconut fiber
by: Marcia C. A. M. Leite, et al.
Published: (2010-01-01)

Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case
by: Yasa Gul Mutlu, et al.
Published: (2023-10-01)

Indications, clinical outcomes and complications of 1,949 flexible bronchoscopies
by: Altair da Silva Costa Jr, et al.

S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS
by: C. Touzeau, et al.
Published: (2022-06-01)

Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1
by: Irene Cattaneo, et al.
Published: (2024-02-01)

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma
by: David M. Foureau, et al.
Published: (2020-07-01)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
by: Katja Seipel, et al.
Published: (2022-03-01)

BCMA-targeted immunotherapy for multiple myeloma
by: Bo Yu, et al.
Published: (2020-09-01)

HIGH-RESOLUTION SPECTROSCOPY OF LONG-PERIODIC ECLIPSING BINARY ε AURIGAE
by: Alex Golovin, et al.
Published: (2007-12-01)

P977: BISPECIFIC CS1-BCMA CAR-T CELLS ARE CLINICALLY ACTIVE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
by: C. Li, et al.
Published: (2022-06-01)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
by: Heng Mei, et al.
Published: (2021-10-01)

A 'lost' chapter in the calculation of Pi: Baron Zach and MS Bodleian 949
by: Wardhaugh, B
Published: (2015)

A 'lost' chapter in the calculation of π: Baron Zach and MS Bodleian 949
by: Wardhaugh, B
Published: (2015)

Decree 6.949/2009: advance or return to the same point in Deaf Education?
by: Regina Maria Souza, et al.
Published: (2012-04-01)

147 Memory phenotype in allogeneic anti-BCMA CAR-T cell therapy (P-BCMA-ALLO1) correlates with in vivo tumor control
by: Yan Zhang, et al.
Published: (2021-11-01)

949 Flexible control of T cell memory and self-renewal by a reversible epigenetic switch
by: Wei Yang, et al.
Published: (2023-11-01)

Preparation and Properties of ε-Fe<sub>3</sub>N-Based Magnetic Fluid
by: Huang Wei, et al.
Published: (2008-01-01)